Improved patient monitoring – with Ultrasound

Ultrasound complements mammography as a standard clinical tool during aftercare, especially when monitoring women with breast cancer.

Automated Breast Volume Scanning with ultrasound, as possible with the ACUSON S2000™ ABVS system, may make a significant contribution to diagnostic confidence for women with dense breast tissue and inconclusive mammograms.
ACUSON S2000 ABVS

Cadence™ contrast pulse sequencing technology (CPS)** provides excellent visualization of the micro-vascularity of lesions in pre- and post-surgical follow-up care.
Cadence ­­Contrast ­­Pulse­­­­ Sequencing ­­Technology­­ (CPS)
Automated ­­Breast­­­­ Scanning ­­(ABS)­­­­

Advanced imaging technologies, such as eSie Touch™ elasticity imaging and Advanced SieClear™ spatial compounding, may provide additional information in the evaluation of patients post treatment.

Excellent diagnostic possibilities – with Magnetic Resonance

Whether fatty or dense breasts or implants – MR systems can help detect the most subtle lesions that might otherwise go unnoticed with other clinical procedures. A comprehensive portfolio of routine and advanced software applications especially for breastcancer care increase diagnostic confidence: Showing excellent fat suppression and providing 3D bilateral breast imaging in sub-millimeter range by stimulating the water spins, our syngo VIEWS (Volume Imaging with Enhanced Water Signal), powered by Tim, provides excellent follow-up possibilities. Physicians benefit from full coverage of both breasts to carefully monitor also the non-affected breast tissue over time and from excellent lateral coverage up to the axillary region. Fast imaging in excellent quality is delivered by syngo VIEWS in combination with syngo GRAPPA, our unique parallel imaging technique, powered by Tim. Due to their 3D isotropic voxels, both breasts can be viewed at the same time and images rotated in all directions for a more accurate diagnosis. Additionally, syngo GRACE is an ideal possibility to monitor the biochemical status of breast lesions after therapy.

syngo ­­VIEWS­­­­
­­syngo­ ­GRACE
Tim ­­Technology­­
MAGNETOM Espree – Pink

Detailed anatomical and functional information – with CT and Molecular Imaging

Scanning for possible metastatic disease throughout the body plays an essential role in follow-up examinations as well. Combining our latest CT scanner SOMATOM Definition AS with syngo CT Oncology, physicians benefit from unparalleled image quality that depicts even the smallest anatomical abnormality. syngo CT Oncology makes follow-up examinations easier and more reliable. Findings in the base line examination can be propagated into the follow-up exam with one click. syngo CT Oncology automatically segments tumors and calculates the change in tumor volume. The automatic segmentation and propagation make results more independent from the individual reader.
SOMATOM Definition AS
syngo CT Oncology

Additional functional information can be obtained with our FDG PET•CT scanning, which helps detect even most subtle local tumor recurrences and distant metastases. And recurring skeletal metastases can be detected and their progress sequentially evaluated using SPECT and SPECT•CT. Thus, our molecular imaging tools help clearly identify any recurrences as early as possible – with only one exam.
PET•CT
SPECT and SPECT•CT
___________________
Images courtesy of the University of Tennessee, Knoxville, Tennessee, USA

Easy patient management and monitoring – with Tumor Markers

When used in conjunction with other clinical procedures, our in-vitro diagnostics solutions aid in the management of breast cancer patients. CEA, CA 15-3 and BR 27.29 are useful tools for monitoring and detecting recurrences in previously treated Stage II or Stage III breast cancer patients. The Serum HER-2/neu test can be used in aftercare to monitor HER-2/neu levels in metastatic breast cancer.
www.siemens.com/herstory

“My first experiences with measuring Serum HER-2/neu for metastatic breast cancer showed that in many cases, after patients were given chemotherapy, if the treatment was working, serum levels would rapidly decrease in the first three to four weeks after treatment. We confirmed our serum readings with a CT scan.”
Jean-Pierre Lotz, MD, Chief Medical Oncologist, Université Pierre et Marie Curie’s Hôpital Tenon, Paris, France